Hutchison China Meditech Limited Blocklisting Six Monthly Return (1384K)

TIDMHCM

RNS Number : 1384K

Hutchison China Meditech Limited

31 December 2020

Blocklisting Six Monthly Return

London: Thursday, December 31, 2020 : Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.  Name of applicant:           Hutchison China MediTech Limited 
2.  Name of scheme:              (a)  Share Option Scheme conditionally adopted 
                                       by Hutchison China MediTech Limited in 
                                       2005 ("2005 HCML Share Option Scheme") 
                                 (b)  Share Option Scheme conditionally adopted 
                                       by Hutchison China MediTech Limited in 
                                       2015 ("2015 HCML Share Option Scheme") 
                                 (c)  Warrant instrument granted by Hutchison 
                                       China MediTech Limited on June 25, 2020 
                                       ("Warrant") 
3.  Period of return:            From June 29, 2020 to December 28, 2020 
4.  Balance under scheme         (a)        2005 HCML Share Option Scheme: 1,738,910 
     from previous return:                   ordinary shares of US$0.1 each 
                                 (b)        2015 HCML Share Option Scheme: 23,130,970 
                                             ordinary shares of US$0.1 each 
5.  The amount by which          (a)  2005 HCML Share Option Scheme: Nil 
     the block scheme has 
     been increased, if 
     the scheme has been 
     increased since the 
     date of the last return: 
                                 (b)  2015 HCML Share Option Scheme: 30,221,458 
                                       ordinary shares of US$0.1 each 
                                 (c)  Warrant: 16,666,670 ordinary shares of 
                                       US$0.1 each 
6.  Number of securities         (a)  2005 HCML Share Option Scheme: 400,000 
     issued/allotted under             ordinary shares of US$0.1 each 
     scheme during period: 
                                 (b)  2015 HCML Share Option Scheme: 80,780 
                                       ordinary shares of US$0.1 each 
                                 (c)  Warrant: nil 
7.  Balance under scheme         (a)  2005 HCML Share Option Scheme: 1,338,910 
     not yet issued/allotted           ordinary shares of US$0.1 each 
     at end of the period: 
                                 (b)  2015 HCML Share Option Scheme: 53,271,648 
                                       ordinary shares of US$0.1 each 
                                 (c)  Warrant: 16,666,670 ordinary shares of 
                                       US$0.1 each 
8.  Number and class of          (a)  25,198,880 ordinary shares of US$0.1 
     securities originally             each admitted on June 17, 2019 (to replace 
     listed and the date               the Company's previous block admission 
     of admission:                     schemes following the Company's share 
                                       subdivision which took effect on May 
                                       30, 2019) 
                                 (b)  16,666,670 ordinary shares of US$0.1 
                                       each admitted on July 6, 2020 
 
 
9.   Total number of securities    727,722,215 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Christian Hogg 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       [phone] 
 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            [phone] 
  Annie Cheng, Vice President                                [phone] 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      [phone] (Mobile) 
                                                              [e-mail] 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            [phone] / [phone] (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
                                                             [e-mail] 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  [phone] (Mobile), [e-mail] / 
                                                              [phone] (Mobile), y [e-mail] 
 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRURRRRRBUUOAA

(END) Dow Jones Newswires

December 31, 2020 02:00 ET (07:00 GMT)